[Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].
作者信息
Zhao F, Cheng L L, Zheng Z, Zhang M C, Cheng S, Xu P P, Wang L, Zhao W L
机构信息
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China Zhao Fang is working at the Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology, Urumqi 830054, China.
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):513-517. doi: 10.3760/cma.j.issn.0253-2727.2022.06.012.
Abstract
摘要
相似文献
1
[Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):513-517. doi: 10.3760/cma.j.issn.0253-2727.2022.06.012.
2
Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Appl Health Econ Health Policy. 2016 Aug;14(4):465-477. doi: 10.1007/s40258-016-0243-4.
3
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Cancer Med. 2019 Nov;8(16):6955-6966. doi: 10.1002/cam4.2555. Epub 2019 Oct 1.
4
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Infection. 2023 Oct;51(5):1577-1581. doi: 10.1007/s15010-023-02039-2. Epub 2023 Apr 19.
5
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ann Hematol. 2023 Jun;102(6):1421-1431. doi: 10.1007/s00277-023-05204-7. Epub 2023 Apr 12.
6
Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
Ann Hematol. 2017 Jul;96(7):1221-1222. doi: 10.1007/s00277-017-3008-8. Epub 2017 Apr 26.
7
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
J Med Econ. 2018 Oct;21(10):960-967. doi: 10.1080/13696998.2018.1489254. Epub 2018 Jul 6.
8
Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
Ann Hematol. 2022 Jan;101(1):209-211. doi: 10.1007/s00277-020-04388-6. Epub 2021 Jan 3.
9
[Standard treatment and future perspectives for follicular lymphoma].
Rinsho Ketsueki. 2022;63(9):1135-1144. doi: 10.11406/rinketsu.63.1135.
10
The optimal management of follicular lymphoma: an evolving field.
Drugs. 2013 Sep;73(13):1395-403. doi: 10.1007/s40265-013-0092-5.
本文引用的文献
1
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26.
2
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z.
3
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.
Hemasphere. 2020 Jun 8;4(3):e398. doi: 10.1097/HS9.0000000000000398. eCollection 2020 Jun.
4
First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Br J Haematol. 2020 Mar;188(6):898-906. doi: 10.1111/bjh.16264. Epub 2019 Dec 2.
5
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Immunity. 2019 Sep 17;51(3):535-547.e9. doi: 10.1016/j.immuni.2019.08.006. Epub 2019 Sep 10.
6
m7FLIPI and targeted sequencing in high-risk follicular lymphoma.
Hematol Oncol. 2019 Dec;37(5):564-568. doi: 10.1002/hon.2674. Epub 2019 Oct 25.
7
M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
Br J Haematol. 2020 Jan;188(2):259-267. doi: 10.1111/bjh.16159. Epub 2019 Aug 18.
8
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.
Oncologist. 2019 Nov;24(11):e1236-e1250. doi: 10.1634/theoncologist.2019-0138. Epub 2019 Jul 25.
9
Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
Ann Hematol. 2019 Sep;98(9):2131-2138. doi: 10.1007/s00277-019-03750-7. Epub 2019 Jul 8.
10
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
J Clin Oncol. 2019 Apr 20;37(12):984-991. doi: 10.1200/JCO.18.00605. Epub 2019 Feb 27.
Zotero 插件